Previous 10 | Next 10 |
2023-10-04 09:11:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nvni Group (NASDAQ: NVNI ) stock is falling on Wednesday after the company recently made its public debut following a special purpose acquisition company (SPAC) merger. ...
2023-10-04 08:45:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Ga...
BETHESDA, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Exec...
BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matth...
2023-09-18 17:06:48 ET Gainers: Gain Therapeutics ( NASDAQ: GANX ) +7% . QuidelOrtho ( QDEL ) +5% . ARS Pharmaceuticals ( SPRY ) +5% . ProFrac Holding ( ACDC ) +5% . Clean Energy Fuels ( CLNE ) +4% . L...
First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx ® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company...
--News Direct-- Bethesda, MD, August 29, 2023 ( PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's ...
(NewsDirect) Bethesda, MD, August 29, 2023 ( PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's dis...
Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presented at the International Congress of Parkinson's Disease a...
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
Gain Therapeutics Inc. Website:
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...